Establishing the Role of Tigecycline in an era of Antimicrobial Resistance

Jason J. Schafer; Debra A. Goff


Expert Rev Anti Infect Ther. 2008;6(5):557-567. 

In This Article

Overview of the Current Market

The prevalence of multidrug-resistant (MDR) bacteria has increased in recent years as the development of novel antimicrobial agents has diminished. Drug-resistant pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus spp.(VRE), Pseudomonas aeruginosa, Acinetobacter baumannii and extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, present therapeutic challenges due to the limited number of antimicrobials with reliable activity. Furthermore, several investigations have concluded that the presence of drug-resistant pathogens can lead to ineffective empiric therapy, thereby contributing to poor patient outcomes. As a result, there is a growing need for the development of new antimicrobial agents with novel mechanisms of action and activity against drug-resistant pathogens. The addition of tigecycline to the current antimicrobial armamentarium will be helpful in meeting some of the challenges posed by bacterial resistance.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.